[December 07, 2017]

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) Market Report - Pipeline Review, H2 2017 - Research and Markets

The "Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

'Protein Phosphatase 2A - Pipeline Review, H2 2017'; Protein Phosphatase 2A (PP2A or EC 3.1.3.16) pipeline Target (News - Alert) constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes.

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Protein Phosphatase 2A (PP2A) is an enzyme encoded by the PPP2CA gene. PP2A plays important roles in regulation of cell cycle, signal transduction, cell differentiation, and transformation. Its activity is related to several diseases, including neurodegenerative diseases and cancer.

The report 'Protein Phosphatase 2A - Pipeline Review, H2 2017' outlays comprehensive information on the Protein Phosphatas 2A (PP2A or EC 3.1.3.16) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

Key Topics Covered:

1. Introduction
2. Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Overview
3. Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Therapeutics Development
4. Products under Development by Stage of Development
5. Products under Development by Therapy Area
6. Products under Development by Indication
7. Products under Development by Companies
8. Products under Development by Universities/Institutes
9. Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Therapeutics Assessment
10. Assessment by Mechanism of Action
11. Assessment by Route of Administration
12. Assessment by Molecule Type
13. Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Companies Involved in Therapeutics Development

• Ampio Pharmaceuticals Inc
• Cyano Biotech GmbH
• Lixte Biotechnology Holdings Inc
• PEP-Therapy SAS (News - Alert)
• Re-Pharm Ltd
• Signum Biosciences Inc

For more information about this report visit https://www.researchandmarkets.com/research/j3bczm/protein?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20171207005917/en/

[ Back To TMCnet.com's Homepage ]